Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-02-01
2005-02-01
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S032000, C424S009362, C424S009610, C536S017200, C536S017300, C536S017400, C540S145000
Reexamination Certificate
active
06849607
ABSTRACT:
Purpurin-carbohydrate conjugates and their method of preparation and use for treatment of cancer cells. The conjugates have the general formula:wherein R6and R7taken together are ═NR11or are independently —OR11, where at least one R11is preferably a mono or polysaccharide moiety and R1-R8are various groups formed from carbon and hydrogen and optionally oxygen and nitrogen where R3and R4may together from a covalent bond.
REFERENCES:
patent: 5952366 (1999-09-01), Pandey et al.
patent: 2 709 491 (1995-03-01), None
patent: WO 99 67249 (1999-12-01), None
Hombrecher et al., “Synthesis and Investigation of Galactopyranosyl-cholesteryloxy Substituted Porphyrin”, Bioorganic and Medicinal Chemistry Letters, vol. 6, No. 11, 1996, pp. 1199-1202.*
Allen, Howard J., et al., “Role of Galaptin in Ovarian Carcinoma Adhesion to Extracellular Matrix in Vitro”, Journal of Cellular Biochemistry, Jan. 17, 1990, pp 43-57, vol. 43.
Andre, S. et al., “Galectins-1 and -3 and their Ligands in Tumor Biology”, J. Cancer Res. Clin. Oncol., 1999, pp 461-474, vol. 125. (Abstract only).
Bachor, R., et al., “Photosensitized Destruction of Human Bladder Carcinoma Cells Treated with Chlorine6-Conjugated Microspheres”, Proc. Natl. Acad. Sci., 1991, pp 1580-1584, vol. 88. (Abstract only).
Barondes, S.H., et al., “Galectins: A Family of Animal β-Galactoside-Binding Lectins”, Cell, 1994, pp 597-598, vol. 76.
Castronovo, V., “Laminin Receptors and Laminin-Binding Proteins During Tumor Invasion and Metastasis”, Invasions & Metastasis, 1993, pp 1-30, vol. 13. (Abstract only).
Chen, Y., et al., “Use of Sialylated or Sulfated Derivatives and Acrylamide Copolymers of Gal Beta 1,3GalNAc Alpha-and GalNAc Alpha- to Determine the Specificieits of Anti-T and Anti-Tn Antibody Levels in Cancer Patients”, Glycoconjugate Journal, 1995, pp 55-62, vol. 12.
Chiariotti, L., et al., “Increased Expression of the Negative Growth Factor, Galactoside-Binding Protein, Gene in Transformed Thyroid Cells, and in Human Thyroid Carcinoma”, Oncogene, 1992, pp 2507-2511, vol. 7.
Chiariotti, L., et al., “Control of Galectin Gene Expression”, Biochimie, 1999, pp 381-388, vol. 81.
Donald, P.J., et al., “Monoclonal Antibody-Porphyrin Conjugate for Head and Neck Cancer; The Possible Magic Bullet”, Otolaryng Head Neck Surg., 1991, pp 781-787, vol. 105 (Abstract only).
Dougherty, T., et al., “Photodynamic Therapy”, J. Natl. Cancer Inst. 1998, pp 889-905, vol. 90.
Engvall, E., “Enzyme Immunoassay ELISA and EMIT”, Methods in Enzymology, 1980, pp 419-439, vol. 70.
Fingar V.H., et al., “Expression of Chemokine Receptors by Endothelial Cells: Detection by Intravital Microscopy Using Chemokine-Located Fluorescent Microspheres”, Methods in Enzymology, 1997, pp 148-158, vol. 288.
Hemming, A.W., et al., “Photodynamic Therapy of Squamous Cell Carcinoma. An evaluation of a New Photosensitizing Agent, Benzoporphyrin Derivative and New Photoimmunoconjugate”, Surg. Oncol., 1993, pp 187-196, vol. 2. (Abstract only).
Henderson, B., et al., “An in Vivo Quantitative Structure-Activity Relationship for a Congeneric Series of Pyropheophorbide Derivatives as Photosensitizers for Photodynamic Therapy”, Cancer Research, 1997, pp 4000-4007, vol. 57.
Hombrecher, H., et al., “Synthesis and Investigations of a Galactopyranosyl-Cholesteryloxy Substituted Porphyrin” Bioorganic & Medicinal Chem. Letters, 1996, pp1199-1202, vol. 6, No. 11.
Illinger, D., et al., “The Kinetic Aspects of Intracellular Fluorescence Labeling with TMA-DPH Support the Maturation Model for Endocytosis in L929 Cells”, The Journal of Cell Biology, 1994, pp 783-794, vol. 125 (Abstract only).
Karagianis, G., et al. “Biophysical and Biological Evaluation of Porphyrin-bisacridine Conjugates” Anti-Cancer Drug Design, 1996, pp 205-220, vol. 11 (Abstract only).
Kessel, D., et al., “Sites of Photodamage in vivo and in vitro by a Cationic Porphyrin”, Photochem. Photobiol., 1995, pp 875-881, vol. 62 (Abstract only).
Kessel, D., et al., “Photodynamic Therapy: A Mitochondrial Inducer of Apoptosis” Cell Differ., 1999, pp 28-35, vol. 6 (Abstract only).
Kozyrev, A.N., et al., “Synthesis and Spectroscopic Studies of Novel Chlorins with Fused Quinoxaline or Benzimidazole Ring Systems and the Related Dimers with Extended Conjugation” Tetrahedron, 2000, pp 3353-3364, vol. 56.
Lahm, H., et al., “Comprehensive Galectin Fingerprinting in a Panel of 61 Human Tumor Cell Lines by RT-PCR and its Implications for Diagnostic and Therapeutic Procedures”, J. Cancer. Res. Clin. Onco., 2001, pp 375-386, vol. 127 (Abstract only).
Leonidas, D.D., et al., “Structural Basis for the Recognition of Carbohydrates by Human Galectin-7”, BIochemistry, 1998, pp 13930-13940, vol. 37.
Liotta, L.A., et al., “Tumor Invasion and Metastasis-Role of the Extracellular Matrix: Rhoads Memorial Award Lecture”, Cancer Res., 1986, pp 1-7, vol. 46.
MacDonald, I., et al., “Subcellular Localization Patterns and their Relationship to Photodynamic Activity of Pyropheophorbide-a Derivatives”, Photochemistry and Photobiology, 1999, pp 789-797, vol. 70.
Magnusson, G., et al., “BF3-Etherate Induced Formation of 2,2,2-Trichlorethyl-Glycopyranosides. Selective Visualization of Carbohydrate Derivatives on TLC Plates”, Acta Chemica Scandinavica B, 1981, pp 213-221, vol. 35.
Morgan, J. et al., “Comparison of Photodynamic Targets in a Carcinoma Cell Line and its Mitochondrial DNA-Deficient Derivative”, Photochem. Photobiol, 2000, pp 747-757, vol. 71.
Pandey, R.K., et al., “Alkyl Ether Analogs of Chlorophyll A Derivatives: Part 1, Synthesis, Photophysical Properties and Photodynamic Efficacy”, Photochemistry and Photobiology, 1996, pp 194-204, vol. 64.
Prendergast, F.G., et al., “1-[4-(trimethylamino)-phenyl]-6-phenylhexa-1, 3, 5-triene: Synthesis, Fluorescence Properties and use as a Fluorescence Probe of :ipid Bilayers”, Biochemistry, 1981, pp 7333-7338, vol. 20.
Rini, J.M., “Lectin Structures”, Annu. Rev. Biophys. Biomol. Struct., 1995, pp 551-577, vol. 24.
Rungta, A., et al., “Purpurinimides as Photosensitizers: Effect of the Presence and Position of the Substituents in the In Vivo Photodynamic Efficacy”, Biorg. Med. Chem. Lett., 2000, pp. 1463-1466, vol. 10.
Sacchettini, J.C., et al., “Multivalent Protein-Carbohydrate Interactions. A New Paradiagm for Supermolecular Assembly and Signal Transduction”, Biochemistry, 2001, pp 3009-3015, vol. 40.
Salvatore, P., et al., “Galectin-1 Gene Expression and Methylation State in Human T Leukemia Cell Lines”, International Journal of Oncology, 2000, pp 1015-1018, vol. 17.
Schmidt-Erfurth, U., et al., “Photodynamic Targeting of Human Retinoblastoma Cell Using Covalent Low Density Lipoprotein Conjugates”, Br. J. Cancer, 1997, pp 54-61, vol. 75. (Abstract only).
Sears, P., et al., “Carbohydrate Mimetics: A New Strategy for Tackling the Problem of Carbohydrate-Mediated Biological Recognition”, Angew. Chem. Intl. Ed. Eng., 1999, pp 2301-2324, vol. 38.
Smith, K.M., “Porphyrins and Metalloporphyrins”, Elsevier Scientific Publications, Amsterdam, 1975, ISBN 044415378 (Table of Contents only).
Sol., V., et al., “Synthesis, Spectroscopy, and Photodytotoxicity of Glycosylated Amino Acid Porphyrin Derivatives as Promising Molecules for Cancer Phototherapy”, J. Org. Chem., 1999, pp 4431-4444, vol. 64.
Van Den Brule, F.A., et al., “Expression of the 67 kD Laminin Receptor, Galectin-1, and galectin-3 in Advanced Human Uterine Adenocarcinoma”, Human Pathology, 1996, pp 1185-1191, vol. 27. (Abstract only).
Vrouenraets, M.B., et al., “Development of Meta-Tetrahydroxyphenylchlorin-Monoclonal Antibod
Dougherty Thomas J.
Pandey Ravindra K.
Dunn Michael L.
Health Research , Inc.
McIntosh III Traviss C.
Wilson James O.
LandOfFree
Galectin recognized photosensitizers for photodynamic therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Galectin recognized photosensitizers for photodynamic therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Galectin recognized photosensitizers for photodynamic therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3480568